GlyProVac is pursuing the development of a glycoprotein based vaccine against Enterotoxigenic Escherichia coli (ETEC).
GlyProVac has raised $467K in total funding. The most recent round was Grant. The last funding was announced in February 2024.
GlyProVac's investors include CARB-X.
GlyProVac is headquartered in Odense, Denmark.
GlyProVac is pursuing the development of a glycoprotein based vaccine against Enterotoxigenic Escherichia coli (ETEC).
GlyProVac is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GlyProVac — Funding & Investors." VCBacked, February 29, 2024, https://www.vcbacked.co/company/glyprovac. Accessed August 16, 2026.
VCBacked. (2024). GlyProVac — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/glyprovac
{{cite web |title=GlyProVac — Funding & Investors |url=https://www.vcbacked.co/company/glyprovac |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated